Autolus Therapeutics plc
AUTLHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Autolus Therapeutics plc focuses on Biotechnology services and products. Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company carries a $561.6M market cap, placing it firmly in the small-cap category. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.
Market Cap
$561.6M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-3.37
EPS (TTM)
$-1.07
EPS (Fwd)
$-0.63
ROE
-29.6%
ROA
-22.3%
Cash
$217.4M
Total Debt
$0
Free CF
—
52W Change
62.3%
Annual Financials
Cash vs Debt
Where AUTL stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, AUTL finished 44.17% above its 150-day moving average ($1.63) and 45.96% above its 200-day moving average ($1.61). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AUTL overbought or oversold?
At the September 1, 2026 close, AUTL's RSI(14) was 50.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Autolus Therapeutics plc reports $217.4M in cash and $0 in total debt. ROE of -29.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $6.2M (2022) to $75.4M (2025), reflecting a 1117% increase over the period.
As with any equity investment, AUTL carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Autolus Therapeutics plc and its sector.